BRAINLIFE.ORG
|
|
|
|
|
Current
Neuro-Oncology
|
|
|
|
Volume
26 Number 1
15 January 2024
|
|
|
|
Home
>
Publications
>
Current
Neuro-Oncology >
Volume
26, Year 2024 >
Number
1, 15 January
|
|
|
|
|
|
Karschnia P, Dono A, Young JS,
Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F,
Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Thon N,
Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R,
Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS,
Esquenazi Y, Tonn JC.
Associations
between recurrence patterns and outcome in glioblastoma patients
undergoing re-resection: A complementary report of the RANO resect
group.
Neuro
Oncol. 2024 Jan
2:noad237. doi:
10.1093/neuonc/noad237. PMID:
38164632. Letter, Observational study˰ ˍ
|
|
|
|
*Zhao L, Qiu Z, Yang Z, Xu
L, Pearce TM, Wu Q, Yang K, Li F, Saulnier O, Fei F, Yu H, Gimple
RC, Varadharajan V, Liu J, Hendrikse LD, Fong V, Wang W, Zhang J,
Lv D, Lee D, Lehrich BM, Jin C, Ouyang L, Dixit D, Wu H, Wang X,
Sloan AE, Wang X, Huan T, Mark Brown J, Goldman SA, Taylor MD,
Zhou S, Rich JN.
Lymphatic
endothelial-like cells promote glioblastoma stem cell growth
through cytokine-driven cholesterol metabolism.
Nat
Cancer.
2024 Jan 3;5(1):147-166. doi:
10.1038/s43018-023-00658-0. PMID:
38172338. Laboratory investigation˰
ˍ
Related
article:
Brewer
G. Cholesterol-fuelled
glioblastoma.
Nat
Rev Cancer.
2024 Jan 31. doi:
10.1038/s41568-024-00672-z. PMID:
38297143. Comment˰ ˍ
|
|
|
|
*Silvani A, Franceschi E.
A
new era after a long wait: Vorasidenib, an inhibitor of mutant
IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori.
2024 Jan 2:3008916231217583. doi:
10.1177/03008916231217583. PMID:
38166539. Editorial. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
|
|
|
|
Zhao S, Zhang M, Zhang Q, Wu J, Dai
H.
Anlotinib
alone or in combination with bevacizumab in the treatment of
recurrent high-grade glioma: a prospective single-arm, open-label
phase II trial.
BMC
Cancer. 2024 Jan
2;24(1):6. doi:
10.1186/s12885-023-11776-4. PMID:
38166698. Interventional study. ˍ
|
|
|
|
Koyuncuer A.
Intraoperative Touch
Imprint Cytology of Brain Neoplasms: A Useful High-Diagnostic Tool
in 93 Consecutive Cases; Differential Diagnoses, Pitfalls, and
Traps.
Anal
Cell Pathol (Amst). 2024 Jan 4;2024:2346092. doi:
10.1155/2024/2346092. PMID:
38440121. Observational study. ˍ
|
|
|
|
Shi ZF, Li KK, Liu AP, Chung NY,
Chow C, Chen H, Kan NA, Zhu XL, Chan DT, Mao Y, Ng HK.
Rare
Pediatric Cerebellar High-Grade Gliomas Mimic Medulloblastomas
Histologically and Transcriptomically and Show p53
Mutations.
Cancers
(Basel). 2024 Jan 4;16(1):232. doi:
10.3390/cancers16010232. PMID:
38201659. Case report. ˍ
|
|
|
|
Stepien N, Mayr L, Schmook MT,
Raimann A, Dorfer C, Peyrl A, Azizi AA, Schramm K, Haberler C,
Gojo J.
Feasibility
and antitumour activity of the FGFR inhibitor erdafitnib in three
paediatric CNS tumour patients.
Pediatr
Blood Cancer.
2024 Jan 4:e30836. doi:
10.1002/pbc.30836. PMID:
38177074. Case report. ˍ
|
|
|
|
*Wang S, Yin F, Guo Z, Li R, Sun W, Wang Y, Geng Y, Sun C, Sun
D.
Association between gut microbiota
and glioblastoma: a Mendelian randomization study.
Front
Genet. 2024 Jan 4;14:1308263. doi:
10.3389/fgene.2023.1308263. PMID:
38239850. Observational study. ˍ
|
|
|
|
Zhang JF, Okai B, Iovoli A,
Goulenko V, Attwood K, Lim J, Hess RM, Abad AP, Prasad D,
Fenstermaker RA.
Bevacizumab
and gamma knife radiosurgery for first-recurrence glioblastoma.
J
Neurooncol. 2024
Jan 4. doi:
10.1007/s11060-023-04524-y. PMID:
38175460. Observational study. ˍ
|
|
|
|
Sun Y, Liu P, Wang Z, Zhang H, Xu
Y, Hu S, Yan Y.
Efficacy
and indications of gamma knife radiosurgery for recurrent low-and
high-grade glioma.
BMC
Cancer. 2024 Jan
5;24(1):37. doi:
10.1186/s12885-023-11772-8. PMID:
38183008. Observational study. ˍ
|
|
|
|
André N, Deley MCL,
Léguillette C, Probst A, Willems L, Travers R, Aerts I,
Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P,
Entz-Werlé N, Leblond P.
METRO-PD1:
Phase 1 study of nivolumab in combination with metronomic
chemotherapy in children and adolescents with relapsing/refractory
solid tumors.
Eur
J Cancer. 2024
Jan 6;198:113525. doi:
10.1016/j.ejca.2024.113525. PMID:
38199147. Interventional study. ˍ
|
|
|
|
Bobholz SA, Hoefs A, Hamburger J,
Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D,
Krucoff M, Banerjee A, LaViolette PS.
Radio-pathomic
maps of glioblastoma identify phenotypes of non-enhancing tumor
infiltration associated with bevacizumab treatment response.
Res
Sq [Preprint].
2024 Jan 8:rs.3.rs-3832221. doi:
10.21203/rs.3.rs-3832221/v1. PMID:
38260400. Observational study. ˍ
|
|
|
|
Naeem A, Aziz N, Nasir M, Rangwala HS, Fatima H, Mubarak
F.
Accuracy of MRI in Detecting 1p/19q
Co-deletion Status of Gliomas: A Single-Center Retrospective
Study.
Cureus.
2024 Jan 8;16(1):e51863. doi:
10.7759/cureus.51863. PMID:
38327950. Observational
study. ˍ
|
|
|
|
Pilbeam KL, Pradhan K, Croop J,
Minard CG, Liu X, Voss SD, Isikwei E, Berg SL, Reid JM, Fox E,
Weigel BJ.
A
phase 1 trial utilizing a pharmacokinetic endpoint to determine
the optimal dose of ramucirumab in children and adolescents with
relapsed or refractory solid tumors, including central nervous
system tumors.
Pediatr
Blood Cancer.
2024 Jan 8:e30817. doi:
10.1002/pbc.30817. PMID:
38189770. Interventional study˰ ˍ
|
|
|
|
Roux A, Elia A, Aboubakr O,
Moiraghi A, Simboli GA, Tauziede-Espariat A, Dezamis E, Parraga E,
Benevello C, Fathallah H, Chretien F, Oppenheim C, Zanello M,
Pallud J.
Efficacy
and Safety of Carmustine Wafer Implantation After Ventricular
Opening in Glioblastomas, Isocitrate Dehydrogenase-Wildtype, in
Adults.
Neurosurgery.
2024 Jan 8. doi:
10.1227/neu.0000000000002817. PMID:
38189433. Observational study˰ ˍ
|
|
|
|
Derby S, Jackson MR, Williams K,
Stobo J, Kelly C, Sweeting L, Shad S, Herbert C, Short SC,
Williamson A, James A, Nowicki S, Bulbeck H, Chalmers
AJ.
Concurrent
olaparib and radiotherapy in elderly patients with newly diagnosed
glioblastoma: the phase I dose escalation PARADIGM trial.
Int
J Radiat Oncol Biol Phys.
2024 Jan 9:S0360-3016(24)00015-4. doi:
10.1016/j.ijrobp.2024.01.011. PMID:
38211641. Interventional study. ˍ
|
|
|
|
Jimenez AE, Chakravarti S, Liu J,
Kazemi F, Jackson C, Gallia G, Bettegowda C, Weingart J, Brem H,
Mukherjee D.
The
Hospital Frailty Risk Score independently predicts postoperative
outcomes in glioblastoma patients.
World
Neurosurg. 2024
Jan 9:S1878-8750(24)00033-0. doi:
10.1016/j.wneu.2024.01.021. PMID:
38211815. Observational study˰ ˍ
|
|
|
|
Li Z, Song Y, Farrukh Hameed NU,
Yuan S, Wu S, Gong X, Zhuang D, Lu J, Zhu F, Qiu T, Zhang J,
Aibaidula A, Geng X, Yang Z, Tang W, Chen H, Zhou L, Mao Y, Wu
J.
Effect
of high-field iMRI guided resection in cerebral glioma surgery: A
randomized clinical trial.
Eur
J Cancer. 2024
Jan 9;199:113528. doi:
10.1016/j.ejca.2024.113528. PMID:
38218157. Interventional study˰ ˍ
|
|
|
|
Hatiboglu MA, Akdur K, Sakarcan A,
Seyithanoglu MH, Turk HM, Sinclair G, Oztanir MN.
Promising
outcome of patients with recurrent glioblastoma after Gamma
Knife-based hypofractionated radiotherapy.
Neurochirurgie.
2024 Jan 10;70(2):101532. doi:
10.1016/j.neuchi.2024.101532. PMID:
38215936. Observational study˰ ˍ
|
|
|
|
Freund BE, Jaeckle K,
Quinones-Hinojosa A, Feyissa AM.
Case
Report: "Aggressive" perioperative antiseizure
medication prophylaxis in patients with glioma-related epilepsy at
high risk of early postoperative seizures following awake
craniotomy.
Front
Surg. 2024 Jan
11;10:1282013. doi:
10.3389/fsurg.2023.1282013. PMID:
38274353. Case report. ˍ
|
|
|
|
Gatto L, Di Nunno V, Tosoni A,
Bartolini S, Ranieri L, Franceschi E.
Vorasidenib
in IDH1/2-mutant low-grade glioma: the grey zone of patient's
selection.
Front
Oncol. 2024 Jan
11;13:1339266. doi:
10.3389/fonc.2023.1339266. PMID:
38273856. Comment. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
|
|
|
|
Neef V, König S,
Becker H, Dubinski D, Flinspach A, Raimann FJ, Weber K,
Ronellenfitsch MW, Konczalla J, Hattingen E, Czabanka M, Senft C,
Zacharowski K, Baumgarten P.
Red
blood cell transfusion in patients undergoing elective primary
glioblastoma
resection.
Blood
Transfus.
2024 Jan 11. doi:
10.2450/BloodTransfus.613. PMID:
38315541. Observational study. ˍ
|
|
|
|
Romano A, Sollazzo F, Rivetti S,
Morra L, Servidei T, Lucchetti D, Attinà G, Maurizi P,
Mastrangelo S, Zovatto IC, Monti R, Bianco M, Palmieri V, Ruggiero
A.
Evaluation
of Metabolic and Cardiovascular Risk Measured by Laboratory
Biomarkers and Cardiopulmonary Exercise Test in Children and
Adolescents Recovered from Brain Tumors: The CARMEP Study.
Cancers
(Basel). 2024 Jan 11;16(2):324.
doi:
10.3390/cancers16020324. PMID:
38254811. Observational study. ˍ
|
|
|
|
Bagley SJ, Binder ZA, Lamrani L,
Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA,
Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W,
Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan
S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K,
Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon
JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated
peripheral infusions of anti-EGFRvIII CAR T cells in combination
with pembrolizumab show no efficacy in glioblastoma: a phase 1
trial.
Nat
Cancer. 2024 Jan
12. doi:
10.1038/s43018-023-00709-6. PMID:
38216766. Interventional study˰ ˍ
|
|
|
|
Galanis E, Dooley KE, Keith
Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ,
Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson
SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC,
Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic
antigen-expressing oncolytic measles virus derivative in recurrent
glioblastoma: a phase 1 trial.
Nat
Commun. 2024 Jan
12;15(1):493. doi:
10.1038/s41467-023-43076-7. PMID:
38216554. Interventional
study. ˍ
|
|
|
|
van der Meulen M, Ramos RC,
Voisin MR, Patil V, Wei Q, Singh O, Climans SA, Kalidindi N, Or R,
Aldape K, Diamandis P, Munoz DG, Zadeh G, Mason WP.
Differences
in methylation profiles between long-term survivors and short-term
survivors
of IDH-wild-type glioblastoma.
Neurooncol
Adv. 2024
Jan 12;6(1):vdae001. doi:
10.1093/noajnl/vdae001. PMID:
38312227. Observational study. ˍ
|
|
|
|
Flies CM, Friedrich M, Lohmann P,
van Garderen KA, Smits M, Tonn JC, Weller M, Galldiks N, Snijders
TJ.
Treatment-associated
imaging changes in newly diagnosed MGMT promoter-methylated
glioblastoma undergoing chemoradiation with or without
cilengitide.
Neuro
Oncol. 2024 Jan
14:noad247. doi:
10.1093/neuonc/noad247. PMID:
38219019. Observational study. ˍ
|
|
|
|
Bhaskaran D, Savage J, Patel A,
Collinson F, Mant R, Boele F, Brazil L, Meade S, Buckle P, Lax S,
Billingham L, Short SC.
A
randomised phase II trial of temozolomide with or without
cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT):
protocol for a multi-centre, double-blind, placebo-controlled
trial.
BMC
Cancer. 2024 Jan
15;24(1):83. doi:
10.1186/s12885-023-11792-4. PMID:
38225549. Interventional
study protocol. ˍ
|
|
|
|
Chen ATC, Serante AR, Ayres AS,
Tonaki JO, Moreno RA, Shih H, Gattás GS, Lopez OVM, Reis
Dos Santos de Jesus G, de Carvalho IT, Marotta RC, Marta GN, Feher
O, Neto HS, Ribeiro ISN, da Conceição Vasconcelos
KGM, Figueiredo EG, Weltman E.
Prospective
Randomized Phase 2 Trial of Hypofractionated Stereotactic
Radiotherapy of 25 Gy in 5 fractions compared to 35 Gy in 5
fractions in the Reirradiation of Recurrent Glioblastoma.
Int
J Radiat Oncol Biol Phys.
2024 Jan 15:S0360-3016(24)00026-9. doi:
10.1016/j.ijrobp.2024.01.013. PMID:
38232937. Interventional
study˰
ˍ
|
|
|
|
*Georgescu MM.
Translation
into Clinical Practice of the G1-G7 Molecular Subgroup
Classification of Glioblastoma: Comprehensive Demographic and
Molecular Pathway Profiling.
Cancers
(Basel). 2024 Jan 15;16(2):361.
doi:
10.3390/cancers16020361. PMID:
38254850. Laboratory investigation, Observational study. ˍ
|
|
|
|
Kikuchi K, Togao O, Yamashita K, Momosaka D, Kikuchi Y, Kuga D,
Yuhei S, Fujioka Y, Narutomi F, Obara M, Yoshimoto K, Ishigami
K.
Comparison of diagnostic performance
of radiologist- and AI-based assessments of T2-FLAIR mismatch sign
and quantitative assessment using synthetic MRI in the
differential diagnosis between astrocytoma, IDH-mutant and
oligodendroglioma, IDH-mutant and
1p/19q-codeleted.
Neuroradiology.
2024 Jan 15. doi:
10.1007/s00234-024-03288-0. PMID:
38224343. Observational study. ˍ
|
|
|
|
Kushihara Y, Tanaka S, Kobayashi Y,
Nagaoka K, Kikuchi M, Nejo T, Yamazawa E, Nambu S, Kugasawa K,
Takami H, Takayanagi S, Saito N, Kakimi K.
Glioblastoma
with high O6-methyl-guanine DNA methyltransferase expression are
more immunologically active than tumors with low MGMT
expression.
Front
Immunol. 2024 Jan
15;15:1328375. doi:
10.3389/fimmu.2024.1328375. PMID:
38288307. Laboratory investigation, Observational study. ˍ
|
|
|
|
Losurdo A, Dipasquale A,
Giordano L, Persico P, Lorenzi E, Di Muzio A, Barigazzi C,
Korolewicz J, Mehan A, Mohammed O, Scheiner B, Pinato DJ, Santoro
A, Simonelli M.
Refining
patient selection for next-generation immunotherapeutic
early-phase clinical trials with a novel and externally validated
prognostic nomogram.
Front
Immunol.
2024 Jan 15;15:1323151. doi:
10.3389/fimmu.2024.1323151. PMID:
38298193. Observational study. ˍ
|
|
|
|
Mastall M, Roth P, Bink A, Fischer
Maranta A, Läubli H, Hottinger AF, Hundsberger T, Migliorini
D, Ochsenbein A, Seystahl K, Imbach L, Hortobagyi T, Held L,
Weller M, Wirsching HG.
A
phase Ib/II randomized, open-label drug repurposing trial of
glutamate signaling inhibitors in combination with
chemoradiotherapy in patients with newly diagnosed glioblastoma:
the GLUGLIO trial protocol.
BMC
Cancer. 2024 Jan
15;24(1):82. doi:
10.1186/s12885-023-11797-z. PMID:
38225589. Interventional
study protocol. ˍ
|
|
|
|
|
|
|
|
|
|
|
Topics
|
|